Semaglutide Price Drop 2027 — What Novo Nordisk's Announcement Means

Novo Nordisk Is Cutting Prices — But Not Until January 2027

In late 2025, Novo Nordisk announced it would reduce the list price of Wegovy and Ozempic by approximately 50%, bringing the monthly cost down to roughly $675 from the current $1,000-$1,349. The new pricing takes effect January 2027.

This is significant news. It is also 8+ months away. Here is what it actually means for you today and what to do in the meantime.

Why the Price Cut?

Several forces converged:

Political pressure: Weight loss medication pricing became a campaign talking point in 2024-2025. Congressional hearings, Medicare negotiation threats, and public outrage over a $1,300/month drug that costs $5 to manufacture created sustained pressure.

Competition: Eli Lilly's tirzepatide (Mounjaro/Zepbound) has been eating into Novo Nordisk's market share. New entrants from Amgen, Viking Therapeutics, and others are approaching FDA approval. Novo needs to compete on price before the market fragments further.

Compounding competition: The growth of compounded semaglutide at $150-$400/month demonstrated that patients will choose affordable alternatives. Novo Nordisk cannot fight compounding pharmacies if their brand pricing is 5-8x higher.

Volume strategy: Lower price, more patients, potentially more revenue. The math only works at scale.

What $675/Month Actually Means

Let me be direct: $675/month is better than $1,300/month. But it is still $8,100/year for a medication many people will take indefinitely.

With insurance: If your insurer covers weight loss medication, this price drop will likely reduce your copay. Plans that previously denied coverage due to cost may reconsider.

Without insurance: $675/month is still unaffordable for most Americans paying cash. It is better, but it is not accessible.

Compared to compounded: Compounded semaglutide currently costs $150-$400/month. Even after the brand price drop, compounded remains 40-75% cheaper.

What Happens to Compounded Semaglutide?

This is the question everyone is asking. Here are the scenarios:

Scenario 1: Shortage designation ends

If the FDA determines the semaglutide shortage is resolved (which the price drop may facilitate by increasing supply), 503A compounding pharmacies lose their legal basis to produce it. 503B outsourcing facilities may still compound under certain conditions, but the landscape narrows significantly.

Scenario 2: Shortage continues

If demand still exceeds supply (possible given price-driven demand increase), compounding continues as currently structured.

Scenario 3: Legal challenge

Novo Nordisk has already attempted to end compounding through FDA petitions. A price drop strengthens their argument that patients can access the brand product. Legal challenges may accelerate in 2027.

My prediction: Compounded semaglutide will remain available through at least mid-2027, but patients should not assume it will be available indefinitely. If you are on compounded semaglutide, have a contingency plan.

Should You Wait for the Price Drop?

No — if you need weight loss treatment now.

Eight months of untreated obesity is eight months of metabolic damage, cardiovascular risk, and quality-of-life impairment. If you are a candidate for GLP-1 medication, the health cost of waiting exceeds the financial cost of starting now.

Compounded semaglutide is available today at $150-$400/month. Start now, benefit now, and reassess your options when brand pricing changes.

Maybe — if your situation is not urgent.

If you are mildly overweight, have no obesity-related comorbidities, and are managing fine with lifestyle interventions, waiting until January 2027 for potentially better insurance coverage is reasonable.

The Bigger Picture

Even at $675/month, semaglutide will remain inaccessible to many Americans without insurance. The systemic issue — that a medication costing $5 to produce is priced at $675 — is not solved by this reduction. It is improved, marginally.

The real access improvements come from:

• Medicare and Medicaid coverage for obesity medications (in progress)
• Employer insurance mandates for weight loss treatment
• Compounding access (while it lasts)
• Next-generation medications from competitors driving prices down further

What to Do Right Now

1. If you want semaglutide today: Compounded formulations from FDA-registered pharmacies are your most affordable, immediately available option. [Start here](/start).

1. If you have insurance: Check whether your plan covers Wegovy or Mounjaro. File an appeal if denied. Some plans have changed their formularies in 2026.

1. If you are on brand-name Wegovy: Use the Novo Nordisk savings card to reduce your current cost while you wait for the official price drop.

1. If you are on compounded semaglutide: Continue. Reassess in Q1 2027 when brand pricing changes and the compounding landscape clarifies.

The Timeline

• Now (April 2026): Compounded semaglutide available at $150-$400/month
• Q3 2026: Watch for FDA shortage designation updates
• January 2027: Novo Nordisk price drop takes effect ($675/month)
• 2027-2028: New competitors reach market, potentially driving prices lower

Weight loss medication will become more accessible over the next 1-2 years. But waiting costs health. Start the conversation now.

[Start here](/start) to explore your current options with a physician who stays on top of these changes.

Related: [Semaglutide cost per month 2026](/blog/semaglutide-cost-per-month-2026) | [Compounded semaglutide — what to know](/blog/compounded-semaglutide-what-to-know)